Evidence map›Paper›PMID 29262552›Full record

ArticleOncotarget2017

Reprogramming of leukemic cell metabolism through the naphthoquinonic compound Quambalarine B.

Karel Vališ, Valéria Grobárová, Lucie Hernychová, Martina Bugáňová, Daniel Kavan, Martin Kalous, Jiří Černý, Eva Stodůlková, Marek Kuzma, Miroslav Flieger and 2 more

Open access · diamondAbstract read
In one paragraph

Article in Oncotarget, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.6field-weighted citation impact, top 36% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 7 citations in OpenAlex.

  1. The therapeutic potential of mitochondrial toxins.The Journal of antibiotics · 2021
    Review
  2. Natural Products Targeting the Mitochondria in Cancers.Molecules (Basel, Switzerland) · 2020
    Review
  3. Targeting ERK-Hippo Interplay in Cancer Therapy.International journal of molecular sciences · 2020
    Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 4 institutions in 1 country.

Karel VališBIOCEV, Institute of Microbiology, v.v.i., The Czech Academy of Sciences, Vestec, Czech Republic.
Valéria GrobárováDepartment of Cell Biology, Faculty of Science, Charles University, Prague, Czech Republic.
Lucie HernychováBIOCEV, Institute of Microbiology, v.v.i., The Czech Academy of Sciences, Vestec, Czech Republic.
Martina BugáňováInstitute of Microbiology, v.v.i., The Czech Academy of Sciences, Prague, Czech Republic.
Daniel KavanDepartment of Biochemistry, Faculty of Science, Charles University, Prague, Czech Republic.
Martin KalousDepartment of Cell Biology, Faculty of Science, Charles University, Prague, Czech Republic.
Jiří ČernýBIOCEV, Institute of Biotechnology, v.v.i., The Czech Academy of Sciences, Vestec, Czech Republic.
Eva StodůlkováInstitute of Microbiology, v.v.i., The Czech Academy of Sciences, Prague, Czech Republic.
Marek KuzmaInstitute of Microbiology, v.v.i., The Czech Academy of Sciences, Prague, Czech Republic.
Miroslav FliegerInstitute of Microbiology, v.v.i., The Czech Academy of Sciences, Prague, Czech Republic.
Jan ČernýDepartment of Cell Biology, Faculty of Science, Charles University, Prague, Czech Republic.
Petr NovákBIOCEV, Institute of Microbiology, v.v.i., The Czech Academy of Sciences, Vestec, Czech Republic.
Charles University · CZCzech Academy of Sciences · CZCzech Academy of Sciences, Institute of Microbiology · CZCzech Academy of Sciences, Institute of Biotechnology · CZ

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Abnormalities in cancer metabolism represent potential targets for cancer therapy. We have recently identified a natural compound Quambalarine B (QB), which inhibits proliferation of several leukemic cell lines followed by cell death. We have predicted ubiquinone binding sites of mitochondrial respiratory complexes as potential molecular targets of QB in leukemia cells. Hence, we tracked the effect of QB on leukemia metabolism by applying several omics and biochemical techniques. We have confirmed the inhibition of respiratory complexes by QB and found an increase in the intracellular AMP levels together with respiratory substrates. Inhibition of mitochondrial respiration by QB triggered reprogramming of leukemic cell metabolism involving disproportions in glycolytic flux, inhibition of proteins O-glycosylation, stimulation of glycine synthesis pathway, and pyruvate kinase activity, followed by an increase in pyruvate and a decrease in lactate levels. Inhibition of mitochondrial complex I by QB suppressed folate metabolism as determined by a decrease in formate production. We have also observed an increase in cellular levels of several amino acids except for aspartate, indicating the dependence of Jurkat (T-ALL) cells on aspartate synthesis. These results indicate blockade of mitochondrial complex I and II activity by QB and reduction in aspartate and folate metabolism as therapeutic targets in T-ALL cells. Anti-cancer activity of QB was also confirmed during

Indexed as

leukemiametabolismmitochondrianaphthoquinonestherapy

Identifiers

PMID29262552
PMCPMC5732718
OpenAlexW2760994301

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.